SPOTLIGHT: Stada buys Russian pharma group

German drug maker Stada has snapped up the Russian pharma group Makiz for €125 million. Already active in the Russian market through its Nizhfarm and Hemofarm units, Stada will gain access to Makiz's production and development facilities. Makiz also has some 50 off-patent products, about half of which are sold as branded drugs. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.